• Since its establishment in December 2011, Brazil's HTA body CONITEC (National Commission of Incorporation of Technologies), has published more than 90 assessments 1 .
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• In its assessments, CONITEC evaluates clinical efficacy, safety, cost-effectiveness and budget impact. Important factors that contribute to the clinical evaluation are evaluated endpoints, sample size, patient population and dosing. The economic assessment primarily focuses on budget impact, given that budgets for public healthcare in Brazil are limited.
• The objective of the present study was to perform an analysis on CONITEC's positive and negative decisions, in order to understand the main decision drivers in HTAs.
• In total, 101 publications were identified through Quintiles' HTA Accelerator database 2 : 67 assessed drugs, 12 procedures or interventions and 11 medical devices. The remaining 11
were clinical guidelines (not included in the analysis). Overall, 46 recommendations were positive and 44 negative. CONITEC assessed appraisals in 21 different therapeutic areas, out of which cancer (19 reports), cardiovascular diseases (13) and respiratory diseases (11) were the most assessed areas (Figure 1 ).
Objectives

Methods
• Brazil has set the way for a more transparent process for technology assessment following a formal process including pharmacoeconomic guidelines. However, insufficient clinical benefits and methodological concerns on the economic evaluation seem to be the key drivers for rejection.
• Full transparency on the evaluation of outcomes is still missing, providing additional complexity for manufacturers towards a positive recommendation. Our results demonstrated a positive relation between acceptance and demonstrated clinical efficacy, as well as a low budget impact. Limitations in the submitted clinical studies, absence of long-term data and safety concerns were key rejection drivers and should be omitted to gain a higher change for a positive recommendation.
• CONITEC seems to follow a specific pathway in their decisions, where clinical effectiveness, safety endpoints and budget impact are analysed in detail. This should be leveraged by manufacturers in order to increase the likelihood of receiving a positive recommendation.
Conclusions
• All assessments published by CONITEC between December 2011 and April 2014 were included in our analysis.
• The assessments were stratified by therapeutic area and assessment type. The rationale for the decisions was analysed for both positive and negative recommendations. Reasons for recommending or rejecting a technology were summarised into categories. • The main reasons for rejection were concerns about the economic evidence (52%, 23/44 reports) and a lack to demonstrate a significant clinical benefit (50%, 22/44 reports) ( Table   3 ). Most of the negative comments were with the clinical evidence, including limitations in the submitted clinical studies (30%, 13/44 reports), absence of long-term data (25%, 11/44 reports) and safety concerns (23%, 10/44 reports). • Low budget impact or costs savings was key for a positive recommendation in 50% of the positive assessments, while high-budget impact was driving a negative recommendation in less than 5% of the negative assessments. High-budget impact was not a key driver for a negative recommendation, since CONITEC accepted multiple drugs with a high-budget impact when a relevant improvement in clinical efficacy or a high unmet need was recognised. A high number of technologies that were accepted with a high budget impact were biologics, including two appraisals on trastuzumab in early and metastatic breast cancer and a multiple drug appraisal of 8 different biologics in rheumatoid arthritis. All of these drugs were recommended under the condition of price reductions. • CONITEC did not establish official cost-effectiveness thresholds, but cost-effectiveness was a driver of a positive recommendation in 3 assessments. In the assessment of HPV vaccine, the cost-effectiveness threshold of the WHO was used as a reference. CONITEC concluded that Hepatitis A vaccine was cost-effective because the costs were below the three times GDP per capita threshold. 2. Quintiles' HTA Accelerator, accessed 10/10/14. This is a proprietary Quintiles online platform which captures information from HTA reports of more than 100 agencies in 32 countries
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